Aldeyra Therapeutics, Inc.

Passed

Class Action Period:
March 17, 2022 - June 20, 2023

Lead Plaintiff Deadline:
September 29, 2023

Case Form

Find Out if You Potentially Qualify for a Financial Reward by filling out the form.

First Name

Last Name

Phone

Street Address

City

State

Zip

Shares Purchased

Purchase Date

Estimated Loss

The submission of this form does not create an attorney-client relationship.

Allegations

The filed complaint alleges that Aldeyra Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that:

(i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of purchased during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in during the relevant time frame, you have until September 29, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.